One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Microbot Medical Inc.
MBOT · NCM · Healthcare · Medical Devices
Current price
$1.04
52-week range
$1.03 - $3.04
Market cap
$69.76M
Balance sheet
Healthy
-11.47x Concerning
Net cash $66.49M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
2 Risks
1 rewards · 2 risks
- Reward Revenue grew 249.1% last year.
- Risk Return on equity was -32.9% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 0.0% (peer median: 0.8%).
What this company does
Microbot Medical Inc.
Microbot Medical Inc. makes robotic systems to help surgeons perform minimally invasive procedures inside blood vessels, like those in the heart or brain. Their main product, LIBERTY, acts like a tiny robot arm that a surgeon controls to guide tools through these vessels. This is important because these advanced tools can help doctors treat conditions more precisely and with less physical impact on the patient.
How the company got here
Microbot Medical Inc. was founded in 2010 with a focus on developing robotic solutions for minimally invasive surgeries. The company's journey has been centered on creating advanced tools that allow doctors to perform complex procedures with greater precision inside blood vessels. Key developments include their LIBERTY endovascular robotic system and the NovaCross technology, aimed at improving outcomes in cardiovascular and neurovascular operations. They have also established collaborations with healthcare institutions like Corewell Health and Emory University to further refine their robotic surgical systems.
What it actually does
Microbot Medical Inc. designs and develops robotic medical devices for minimally invasive surgery. These are specialized tools that help surgeons perform procedures inside the body, particularly within blood vessels, without needing large incisions. Think of it like a tiny, remote-controlled robot that a doctor can guide through the body's natural pathways to reach a specific area for treatment or diagnosis.
Endovascular Robotic Surgical Systems
This is the company's primary business line, focused on its LIBERTY system. LIBERTY is a robotic platform designed to help surgeons precisely control guidewires and microcatheters (tiny tubes) within the body's blood vessels. This technology is crucial for procedures in areas like the heart, brain, and limbs, where delicate navigation is essential for treating conditions such as blockages or aneurysms. The system aims to enhance a surgeon's ability to maneuver these instruments with greater accuracy and stability.
Intraluminal Revascularization Devices
This segment involves the NovaCross technology, which is an intellectual property focused on devices used to reopen blocked blood vessels. NovaCross includes an anchoring mechanism to keep the device in place and an integrated microcatheter for delivering treatment. The goal is to restore blood flow in vessels that have become narrowed or blocked, a common issue in cardiovascular and peripheral artery diseases. This technology complements their robotic systems by providing tools for specific therapeutic interventions.
What management is betting on now
Management is focused on advancing the development and adoption of their robotic surgical technologies, particularly the LIBERTY system. They are investing in research and development, often in partnership with leading medical institutions, to enhance the capabilities of their devices. The strategy involves proving the clinical benefits and economic advantages of their robotic solutions to healthcare providers, aiming to establish Microbot Medical as a key player in the growing field of robotic-assisted minimally invasive surgery.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-2.76M
FY2024 Q4
$-1.70M
FY2025 Q1
$-2.89M
FY2025 Q2
$-2.58M
FY2025 Q3
$-3.85M
FY2025 Q4
$-3.78M
FY2026 Q1
$-5.16M
FY2026 Q2
$-5.13M
Revenue
$241.00K
Net income
$-5.63M
Diluted EPS
-0.08
Operating cash flow
$-4.99M
Free cash flow
$-5.13M
Fetching…
Sources
Revenue
$105.00K
Net income
$-3.67M
Diluted EPS
-0.05
Operating cash flow
$-5.05M
Free cash flow
$-5.16M
Fetching…
Sources
Revenue
—
Net income
$-3.46M
Diluted EPS
-0.04
Operating cash flow
$-3.76M
Free cash flow
$-3.78M
Fetching…
Sources
Revenue
—
Net income
$-3.58M
Diluted EPS
-0.07
Operating cash flow
$-3.84M
Free cash flow
$-3.85M
Fetching…
Sources
Revenue
—
Net income
$-3.50M
Diluted EPS
-0.10
Operating cash flow
$-2.57M
Free cash flow
$-2.58M
Fetching…
Sources
Revenue
—
Net income
$-2.60M
Diluted EPS
-0.08
Operating cash flow
$-2.87M
Free cash flow
$-2.89M
Fetching…
Sources
Revenue
—
Net income
$-3.39M
Diluted EPS
-0.19
Operating cash flow
$-1.69M
Free cash flow
$-1.70M
Fetching…
Sources
Revenue
—
Net income
$-3.21M
Diluted EPS
-0.20
Operating cash flow
$-2.76M
Free cash flow
$-2.76M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.04
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $66.5M - more cash than debt. Interest coverage -11.5x.
Net debt
$-66.49M
Interest coverage
-11.47x
Microbot Medical Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 2 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
MBOT
BASELINE
Microbot Medical Inc.
Total debt $876.00K Interest coverage -11.47x This is the baseline the peer rows are being compared against.
Total debt $0.00 Interest coverage 8.05x This peer still has a real interest-payment cushion, while MBOT does not.
Total debt $15.45B Interest coverage 8.33x This peer still has a real interest-payment cushion, while MBOT does not.
Total debt $739.25M Interest coverage -27.67x Neither company has much profit cushion over interest right now.
Total debt $1.13B Interest coverage 0.06x This peer still has a real interest-payment cushion, while MBOT does not.
What you should know
The case for and against MBOT
1 Reward
2 Risks
Rewards
-
Revenue grew 249.1% last year.
Risks
-
Return on equity was -32.9% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 0.0% (peer median: 0.8%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-3.42x
P/B
1.01x
P/S
201.63x
EV/EBITDA
-0.18x
PEG ratio
0.70x
Profitability
How much profit each dollar creates
Gross margin
-185.3%
Operating margin
-2,567.6%
Net margin
0.0%
ROE
-32.9%
ROA
-21.7%
Health
Liquidity and balance-sheet strength
Debt / equity
0.01x
Current ratio
18.56x
Quick ratio
17.37x
Total debt
$876.00K
Total cash
$67.37M
Growth
How the business has been compounding
Revenue TTM
$408.07K
Revenue 5Y CAGR
-44.4%
EPS TTM
-0.25
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-17.64M
Free CF TTM
$-13.11M
FCF margin
-3,211.7%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—